IO Biotech, Inc. (IOBTQ) Net Income towards Common Stockholders (2020 - 2025)

IO Biotech (IOBTQ) has 6 years of Net Income towards Common Stockholders data on file, last reported at -$8.4 million in Q3 2025.

• Quarterly Net Income towards Common Stockholders rose 65.11% year-over-year to -$8.4 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was -$88.3 million (up 2.2% YoY) and the FY2024 annual result came in at -$95.5 million, down 10.93% from the prior year.
• Net Income towards Common Stockholders advanced to -$8.4 million in Q3 2025, from -$26.2 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of -$5.6 million in Q1 2021 to a low of -$40.5 million in Q2 2021.
• A 5-year average of -$20.3 million and a median of -$20.7 million in 2024 frame the typical range for Net Income towards Common Stockholders.
• Annual changes were most pronounced in 2021 — Net Income towards Common Stockholders plunged 554.72% — and 2025, when it surged 65.11%.
• Tracing IOBTQ's Net Income towards Common Stockholders over 5 years: stood at -$22.4 million in 2021, then climbed by 10.44% to -$20.1 million in 2022, then slumped by 30.45% to -$26.2 million in 2023, then slipped by 19.67% to -$31.3 million in 2024, then soared by 73.26% to -$8.4 million in 2025.
• The last three Net Income towards Common Stockholders figures came in at -$8.4 million (Q3 2025), -$26.2 million (Q2 2025), and -$22.4 million (Q1 2025), per Business Quant data.